TY - JOUR
T1 - Safety of cranial radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung cancer patients: A systematic review
AU - Hendriks, Lizza E. L.
AU - Schoenmaekers, Janna
AU - Zindler, Jaap D.
AU - Eekers, Danielle B. P.
AU - Hoeben, Ann
AU - De Ruysscher, Dirk K. M.
AU - Dingemans, Anne-Marie C.
PY - 2015/7
Y1 - 2015/7
N2 - Recently, non-small cell lung cancer (NSCLC) has been partly subclassified into molecularly-defined oncogene "addicted" tumors for which targeted agents are available. Tyrosine kinase inhibitors (TKI) are currently approved for patients with an activating epidermal growth factor receptor (EGER) mutation or anaplastic lymphoma kinase (ALK) rearrangement. In these patients, brain metastases are often the first site of progression while on TKI treatment. The TKI may however still be active on extra-cranial sites and clinicians are thus faced with the question if the TKI may be continued during cranial radiotherapy. Advantages of combining TKI with cranial radiotherapy would be a possible synergistic effect on the brain metastases and the prevention of a systemic disease flare-up. A disadvantage is the possibly increased risk of (neuro)toxicity. The present systematic review addresses the toxicity of combining TKI with cranial radiotherapy in NSCLC patients.
AB - Recently, non-small cell lung cancer (NSCLC) has been partly subclassified into molecularly-defined oncogene "addicted" tumors for which targeted agents are available. Tyrosine kinase inhibitors (TKI) are currently approved for patients with an activating epidermal growth factor receptor (EGER) mutation or anaplastic lymphoma kinase (ALK) rearrangement. In these patients, brain metastases are often the first site of progression while on TKI treatment. The TKI may however still be active on extra-cranial sites and clinicians are thus faced with the question if the TKI may be continued during cranial radiotherapy. Advantages of combining TKI with cranial radiotherapy would be a possible synergistic effect on the brain metastases and the prevention of a systemic disease flare-up. A disadvantage is the possibly increased risk of (neuro)toxicity. The present systematic review addresses the toxicity of combining TKI with cranial radiotherapy in NSCLC patients.
KW - Tyrosine kinase inhibitor
KW - NSCLC
KW - Cranial radiotherapy
KW - Neurotoxicity
KW - EGFR
KW - ALK
U2 - 10.1016/j.ctrv.2015.05.005
DO - 10.1016/j.ctrv.2015.05.005
M3 - Article
C2 - 25990950
SN - 0305-7372
VL - 41
SP - 634
EP - 645
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
IS - 7
ER -